Schizophrenia Drug Market Forecast to 2031: The Entry of Adjunctive Therapies to Shape the Schizophrenia Market [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
Dublin, Dec. 27, 2024 (GLOBE NEWSWIRE) -- The "Schizophrenia: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the schizophrenia market through 2031. The global schizophrenia marketplace is forecast to experience steady growth during the forecast period. This growth will be driven primarily by the launch of five adjunctive therapies that are designed to be used in combination with the other marketed antipsychotics. These include Neurocrine Biosciences' Ingrezza (valbenazine) and NBI-1117568, Bristol Myers Squibb's Cobenfy (trospium chloride + xanomeline), and Boehringer Ingelheim's Iclepertin/BI-425809. Although the majority of the therapies that are already in the market are genericized, patent expiries of long-acting injectable (LAI) atypical antipsychotics such as Abilify Maintena and Arista
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. Selects PANTHERx®Rare Specialty Pharmacy for Distribution of Crenessity™ (crinecerfont) [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $160.00 price target on the stock.MarketBeat
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Barclays PLC from $160.00 to $165.00. They now have an "overweight" rating on the stock.MarketBeat
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaPR Newswire
NBIX
Earnings
- 10/30/24 - Beat
NBIX
Sec Filings
- 12/20/24 - Form 8-K
- 12/19/24 - Form 4
- 12/19/24 - Form 4
- NBIX's page on the SEC website